The War on Cancer: 55 Years, $160 Billion, and No Cure for Major Late-Stage Cancer
Comparing air travel progress with cancer treatment outcomes in America
In 1903 the Wright brothers made the first powered flight of 100 feet at 8 foot altitude. Within 55 years, air travel had rapidly improved to trans-Atlantic commercial jet travel. Let’s compare the progress of air travel to the progress in treating cancer. Essentially, after spending $190 billion in research at the National Cancer Institute over the past 55 years, the war on cancer has produced no cures for any major late-stage cancer.
Cancer remains the number two cause of death. Nearly half of all Americans will develop cancer in their lifetime. Cancer treatment outcomes have succeeded in several obscure categories: childhood leukemias and Hodgkin’s lymphoma. Yet survival rates in the main cancers of breast, lung, colon, and prostate remain virtually unchanged. Co-pay for cancer patients is financially and emotionally draining. Quality of life for chemo patients is seriously compromised. To quote John Bailar, MD, PhD of Harvard University: “The war on cancer has been a qualified failure.”
“Insanity is doing the same thing over and over and expecting a different result.” — Albert Einstein
Why Cancer Treatment Has Stalled: Ignoring the Root Cause
Cancer treatment ignores the etiology, or the cause of the disease. No one with a headache is suffering from a deficiency of aspirin. No one with breast cancer is suffering from a deficiency of chemotherapy. The causes of cancer are complex and essentially ignored in modern oncology. Etiology includes nutrition, stress, toxins, dysbiosis, sedentary lifestyle, disorders of light exposure, and more. Chemo, radiation, and surgery have failed in the war on cancer and it is time to explore more rational options, such as outlined in my books Beating Cancer with Nutrition and 12 Keys to a Healthier Cancer Patient.
On December 23, 1971, President Richard Nixon signed the National Cancer Act, formally declaring a national “war on cancer.” At the time, Congress hoped cancer could be largely eradicated by the nation’s bicentennial in 1976. More than fifty years later, the disease remains the second leading cause of death in the United States, though the statistical picture is considerably more nuanced than early pessimism or optimism would suggest.
2.1M
Projected new cancer cases in the U.S. in 2026
626,140
Projected U.S. cancer deaths in 2026
445.8
New cases per 100,000 people (2018–2022 avg.)
145.4
Deaths per 100,000 people (2019–2023 avg.)
The overall cancer incidence rate — the rate of new diagnoses — declined only modestly (approximately 8.6% between 2000 and 2022), and it continues to rise in certain groups including adults under age 50 and women.
U.S. Cancer Incidence & Age-Adjusted Mortality Rate (per 100,000)
Selected benchmark years, 1970–2024. Sources: NCI SEER, American Cancer Society, NCHS.
The overall cancer death rate is higher among men (171.5 per 100,000) than women (126.3 per 100,000). Cancer mortality is highest among non-Hispanic Black men (203.6 per 100,000) and lowest among non-Hispanic Asian/Pacific Islander women (83.1 per 100,000), underscoring persistent and significant racial and geographic disparities in outcomes.
National Cancer Institute: 50 Years of Federal Investment
The National Cancer Act of 1971 instigated a sustained federal commitment to cancer research that has grown from approximately $500 million in 1972 to $7.35 billion in fiscal year 2026. Cumulatively, the NCI has received approximately $160 billion in appropriations since 1971.
~$160B
Total NCI appropriations since 1971 (nominal dollars)
$7.35B
NCI appropriation for fiscal year 2026
$500M
NCI budget at the time of the National Cancer Act (1972)
NCI Annual Appropriations: Selected Years (in $ billions)
Source: NCI Budget Fact Books, NCI Office of Budget and Finance.
The Cost of Cancer Therapy in America
The financial burden of cancer care represents one of the largest and fastest-growing segments of American healthcare spending. National costs for cancer care were estimated at approximately $190.2 billion in 2015, projected to reach $208.9 billion in 2020 (even holding treatment costs constant, simply due to population aging and growth), and now projected to exceed $245–246 billion by 2030.
In terms of direct pharmaceutical spending, the U.S. spent $99 billion on anticancer therapies in 2023 — orally and clinician-administered drugs, excluding supportive care — and that figure is projected to increase to $180 billion by 2028. Rising drug costs are driven primarily by high launch prices for novel therapeutics and price increases of existing products, often absent new evidence of clinical benefit. Prices for new cancer drugs rose 35% from 2022 to 2023 alone.
$246B+
Projected total cancer care costs in the U.S. by 2030
$99B
Spent on anticancer drug therapies alone in 2023
$16B
Patient out-of-pocket cancer treatment costs annually
$283K
Average annual cost of a newly approved cancer drug (2022)
Patients with cancer lost nearly $5 billion in 2019 due to time costs — the value of time spent traveling to and from care, waiting, and receiving treatment. Cancer patients are 2.5 times more likely to declare bankruptcy and 71% more likely to experience a severe adverse financial event than healthy individuals. Forty percent of cancer patients report difficulty paying medical bills.
Cancer Incidence in America Today
As of 2026, approximately 2,114,850 new cancer cases are projected to be diagnosed in the United States — the equivalent of more than 5,793 new diagnoses every single day. The rate of new cases stands at 445.8 per 100,000 men and women per year.
According to the National Cancer Institute, nearly 2 out of every 5 Americans will be diagnosed with cancer at some point during their lifetime. The specific lifetime risk is approximately 42% for men born in the United States and 40% for women — meaning that cancer is less a rare catastrophic event than a nearly expected feature of a long American life.
~40%
Percentage of Americans who will develop cancer in their lifetime (NCI)
42%
Lifetime cancer risk for American men
40%
Lifetime cancer risk for American women
18.6M
Americans currently living with a history of cancer (2025)
The states with the highest cancer incidence rates are Kentucky, Iowa, and West Virginia, while the lowest rates are found in New Mexico, Arizona, and Nevada, reflecting broad geographic disparities influenced by tobacco use, diet, environmental exposures, and access to healthcare.
Americans in the Cancer Pipeline
The “cancer pipeline” encompasses all individuals who are either actively receiving treatment, under monitoring after treatment, or in active surveillance or watchful waiting. As of 2025, an estimated 18.6 million Americans are living with a history of cancer — either currently in active treatment or in various stages of post-treatment monitoring and survivorship. That population is projected to grow to approximately 26 million by 2030.
Of those currently counted among cancer survivors in the U.S., a substantial portion are in active surveillance rather than active therapy. Active surveillance for low-risk prostate cancer, for example, rose from 14% in 2010 to 51% in 2020 as clinical evidence supported watchful waiting over immediate aggressive intervention. This represents a meaningful cultural and clinical shift in oncology — from presuming treatment is always better to recognizing that monitoring can spare patients significant treatment toxicity.
18.6M
Americans living with cancer history (active treatment + surveillance) in 2025
~26M
Projected by 2030
51%
Low-risk prostate cancer patients now on active surveillance vs. 14% in 2010
2.1M
New patients entering the pipeline each year (2026 projection)
The Four Primary Cancers in America
Four cancer types — breast, prostate, lung/bronchus, and colorectal — collectively accounted for nearly half of all new cancer cases diagnosed in the U.S. in 2022. Together, they also represent the majority of cancer care expenditure, with national medical service costs largest among female breast, colorectal, lung, and prostate cancers.
| Cancer Type | Est. New Cases (2024) | 5-Year Survival Rate | Primary Risk Factors |
|---|---|---|---|
| Breast Cancer (Most common in women) | ~313,000 (female) | ~91% (all stages) ~99% (localized) | Hormonal factors, genetics (BRCA), obesity, alcohol |
| Prostate Cancer (Most common in men) | ~299,010 | ~97% (all stages) ~100% (localized) | Age, family history, African American ancestry |
| Lung & Bronchus Cancer (Deadliest for both sexes) | ~234,580 | ~25% (all stages) ~63% (localized) | Tobacco use (80%+ of cases), radon, occupational exposures |
| Colorectal Cancer | ~152,810 | ~65% (all stages) ~91% (localized) | Diet, sedentary lifestyle, obesity, inflammatory bowel disease, age |
Estimated New Cases: Top 4 Cancers vs. All Others (2024)
Source: American Cancer Society Cancer Facts & Figures 2024; CA: A Cancer Journal for Clinicians.
Lung cancer, despite being third in incidence, remains by far the deadliest — responsible for approximately 125,070 deaths in 2024 (65,790 men; 59,280 women). A person diagnosed with lung and bronchus cancer has approximately a 25% chance of surviving five years, a stark contrast to the near-100% survival rates for localized prostate cancer.
Average Cost of Cancer Treatment Per Patient
Estimating the “average” cost of cancer treatment is inherently imprecise because costs vary enormously by cancer type, stage at diagnosis, treatment modality, institution, and geographic location. However, several data points define the landscape:
~$150K
Frequently cited average total treatment cost across cancer types (AARP)
$283K/yr
Average annual cost of a newly approved cancer drug (2022)
$35,243
Out-of-pocket costs for Stage 4 lung cancer patient over 3 years (Medicare)
$1K–$12K+
Typical monthly cost of chemotherapy drugs
Costs are highest during the first year after diagnosis. For patients with late-stage cancer, a single drug therapy can exceed $10,000–$15,000 per month, translating to annual out-of-pocket costs of $10,000–$20,000 even with insurance. Newly approved cancer drugs in 2022 averaged $283,000 per year — a 53% increase over the $185,620 average in 2017.
Cancer patients bear approximately $16 billion in aggregate out-of-pocket costs annually. Roughly 20% of cancer patients and families surveyed estimated spending more than $20,000 per year in total out-of-pocket expenses, while 40% of patients reported difficulty paying medical bills.
Who Pays? Medicare, Insurance, and Out-of-Pocket Costs
Cancer treatment costs in America fall across a three-way matrix of payers: Medicare (for patients 65 and older or with qualifying disabilities), private commercial insurance, and the patient themselves through out-of-pocket costs. There is no single payer, and the financial burden on patients remains substantial regardless of coverage type.
The Silent Cancer Driver Most Doctors Never Mention
Medicare Coverage
Medicare is the largest single payer of cancer treatment in the U.S., reportedly covering nearly half of the roughly $74 billion spent annually on cancer treatment within its beneficiary population. Coverage is structured across the program’s parts:
Part A (hospital insurance) covers inpatient cancer care, surgically implanted prostheses post-mastectomy, hospice care, and skilled nursing following hospitalization. The 2026 Part A deductible is $1,736 per benefit period.
Part B (medical insurance) covers outpatient chemotherapy (IV or injected), radiation therapy, physician visits, diagnostic imaging, and certain cancer drugs. After a $283 annual deductible, Medicare pays 80% of approved costs — leaving the beneficiary responsible for 20% coinsurance with no annual cap under Original Medicare. For a patient with $200,000 in cancer care costs in a year, the 20% patient share would be $40,000 with no ceiling.
Part D (prescription drugs) covers oral chemotherapy and cancer medications. Beginning in 2026, a new out-of-pocket cap of $2,100 annually limits total spending on Part D medications, a significant consumer protection for oral cancer therapy.
Medicare Advantage (Part C) plans must cover all services covered by Original Medicare but frequently impose prior authorization requirements, tighter networks, and step-therapy restrictions that can delay cancer treatment. A 2023 study found Medicare Advantage enrollees with cancer were more likely than traditional Medicare enrollees to report financial strain and difficulty paying medical bills.
Coverage Gap Warning
Under Original Medicare Parts A and B without supplemental (Medigap) coverage, there is no annual out-of-pocket maximum. A cancer patient receiving $15,000/month in infused chemotherapy would owe $2,000/month (20%) indefinitely. Medigap plans — particularly Plan G — can cover this 20% coinsurance, effectively converting catastrophic exposure into a predictable monthly premium. Patients without Medigap face some of the most severe financial risk in American healthcare.
Uninsured and Underinsured
Cancer patients without adequate coverage face catastrophic financial exposure. The uninsured and underinsured often present with more advanced disease due to foregone screening and delayed care, creating a compounding cycle of worse outcomes and higher eventual costs.
Areas of Progress in Cancer Treatment Over 50 Years
Despite the sobering statistics on incidence and cost, the past half-century has produced genuine and in some cases remarkable advances in cancer biology, early detection, and treatment. These advances have been uneven — spectacularly effective for some cancers, minimally impactful for others — but they represent the genuine achievements of a massive sustained research enterprise.
1970s–80s
Combination Chemotherapy for Hematologic CancersRegimens such as MOPP (mechlorethamine, vincristine, procarbazine, prednisone) for Hodgkin lymphoma and multi-drug protocols for pediatric acute lymphoblastic leukemia (ALL) transformed previously fatal diagnoses into highly curable cancers. Hodgkin lymphoma now has a cure rate exceeding 85%. Childhood ALL 5-year survival rose from below 10% in the 1960s to over 90% today — one of oncology’s most celebrated achievements.
1980s–90s
Screening and Early Detection Widespread adoption of mammography, Pap smears, and PSA testing (despite its controversies) enabled earlier-stage diagnoses when surgery alone can be curative. Colonoscopy screening for colorectal cancer achieved both early detection and prevention through removal of precancerous polyps.
1997
Rituximab (First Targeted Therapy for B-Cell Lymphomas)FDA approval of rituximab — a monoclonal antibody targeting the CD20 protein — marked the beginning of the targeted therapy era. It dramatically improved outcomes in non-Hodgkin lymphoma and chronic lymphocytic leukemia, and validated the principle of blocking specific molecular targets rather than broadly poisoning all dividing cells.
2001
Imatinib (Gleevec) for Chronic Myeloid LeukemiaFDA approval of imatinib for CML is widely considered the most transformative targeted therapy success in oncology history. By specifically inhibiting the BCR-ABL fusion protein driving CML, imatinib converted a uniformly fatal disease into a manageable chronic condition with near-normal life expectancy for most patients — a proof of concept for precision oncology.
2010s
Immune Checkpoint Inhibitors The FDA approvals of ipilimumab (anti-CTLA-4, 2011), nivolumab and pembrolizumab (anti-PD-1, 2014–2015) opened a new era of cancer immunotherapy. In metastatic melanoma — a disease with a median survival of approximately 9 months before 2011 — 5-year survival rates improved dramatically, with some patients achieving durable long-term remissions previously considered impossible. Pembrolizumab and similar agents have since been approved across more than a dozen cancer types.
Selenium Benefits 2026: Proven Cancer Prevention and Autoimmune Relief
2017
CAR-T Cell Therapy Chimeric antigen receptor T-cell therapy, which engineers a patient’s own immune cells to recognize and kill cancer cells, received its first FDA approval in 2017 for relapsed/refractory pediatric ALL and large B-cell lymphoma. Some patients with previously untreatable blood cancers achieved complete remissions. CAR-T represents the most complex and expensive cellular medicine yet deployed in clinical practice, with treatment costs exceeding $400,000–$500,000 for a single course.
2022–2026
Personalized Medicine, Liquid Biopsies, and AI-Assisted Diagnostics Genomic profiling of tumors now enables selection of targeted therapies based on a tumor’s specific mutations rather than its tissue of origin. Liquid biopsies (detection of circulating tumor DNA in blood) are enabling earlier detection of minimal residual disease and recurrence. Artificial intelligence is being integrated into radiology and pathology workflows to improve diagnostic accuracy and speed.
Is There a Cure for Any Major Late-Stage Cancer?
The word “cure” is used carefully — and often avoided — in oncology. Clinically, the field distinguishes between complete remission (no detectable evidence of disease), no evidence of disease (NED), and a statistical cure (typically defined as remaining in complete remission for five or more years with no recurrence). Even a patient in complete remission for years may harbor undetectable microscopic cancer cells. Oncologists cannot state with certainty that cancer will never return, which is why “cured” is rarely the operative term.
cancer
With that caveat, several cancer types have high enough long-term survival rates that many patients are considered functionally cured:
| Cancer / Stage | 5-Year Survival | Assessment |
|---|---|---|
| Testicular cancer (all stages) | >95% | Highly curable even when metastatic; cisplatin-based regimens are remarkably effective |
| Hodgkin lymphoma | ~89% | Cure rates exceed 85%; prior leading cause of cancer death in young adults |
| Thyroid cancer (differentiated) | ~99% (localized) | Slow-growing; surgery plus radioactive iodine is highly effective |
| Childhood ALL (leukemia) | >90% | Cure rates >90% in children; the paradigm case for combination chemotherapy |
| Early-stage breast cancer (localized) | ~99% | Surgery and adjuvant therapy provide very high long-term control |
| Stage IV metastatic breast cancer | ~29% | Controllable but not considered curable; goal is prolonged quality life |
| Stage IV lung cancer | ~7–8% | Immunotherapy has improved outcomes dramatically but cure remains rare |
| Pancreatic cancer (all stages) | ~12% | Among the lowest survival rates; limited effective treatment options |
| Glioblastoma (brain) | ~5–7% | Among the most treatment-resistant solid tumors; median survival ~15 months |
The honest answer remains: there is no reliable cure for most major cancers once they have reached Stage IV (widespread metastasis). The goal in advanced disease has shifted from cure to long-term control — extending life, maintaining quality of life, and converting formerly acute fatal diagnoses into chronic manageable conditions.
The Limited Effectiveness of Chemotherapy: What the Research Shows
Chemotherapy remains the most widely deployed systemic cancer treatment in America, yet a significant body of peer-reviewed evidence documents its limited contribution to overall survival in many adult cancers — and raises serious questions about how that limitation has been communicated to patients and policymakers.
Epigenetics: You Are Not A Prisoner of Your Genes
KEY STUDY — MORGAN, WARD & ROBSON (2004)
A landmark analysis published in Clinical Oncology (Royal College of Radiologists) examined randomized clinical trials reporting 5-year survival benefits attributable solely to cytotoxic chemotherapy in 22 major adult malignancies, using cancer registry data from Australia and U.S. SEER data for 1998. The study concluded that chemotherapy contributed to 5-year survival in only 2.1% of adult cancer cases in Australia and 2.3% in the United States — findings that generated significant controversy but have not been substantially refuted methodologically.
PubMed: PMID 15630849 — Clin Oncol (R Coll Radiol). 2004 Dec;16(8):549-60
END-OF-LIFE CHEMOTHERAPY — PMC STUDY
A retrospective observational study examining chemotherapy administered in the last 90 days of life found that treated patients were significantly more frequently hospitalized and more likely to die in hospital wards compared to untreated patients. The authors identified chemotherapy at end of life as a medical and economic challenge with limited survival benefit but substantial cost and care intensity.
PMC12380927 — Evaluation of end-of-life chemotherapy
IMMUNOTHERAPY VS. CHEMOTHERAPY IN NSCLC — PMC
A study of advanced non-small cell lung cancer patients with high PD-L1 expression found no overall survival advantage for chemoimmunotherapy vs. immunotherapy alone in some subgroups, suggesting that adding chemotherapy does not universally confer benefit and highlighting the need for better patient selection strategies.
PMC10149619 — Chemoimmunotherapy vs. immunotherapy for NSCLC
Sources:
National Cancer Institute (cancer.gov); NCI Budget Fact Books (1971–2026);
American Cancer Society Cancer Facts & Figures 2024/2026;
CA: A Cancer Journal for Clinicians (Siegel et al., 2024, 2026);
PubMed Central; NCBI Bookshelf;
AACR Cancer Progress Report 2024;
USAFacts;
PMC indexed studies as cited above.
PBS, NPR, CDC, and Wikipedia were excluded per report parameters.
